These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39128186)

  • 1. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
    Nasca V; Prinzi N; Coppa J; Prisciandaro M; Oldani S; Ghelardi F; Conca E; Capone I; Busico A; Perrone F; Tamborini E; Sabella G; Greco G; Greco FG; Tafuto S; Procopio G; Morano F; Niger M; Maccauro M; Milione M; de Braud F; Pietrantonio F; Pusceddu S
    Eur J Cancer; 2024 Sep; 209():114276. PubMed ID: 39128186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
    O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
    Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
    Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
    Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.
    Park YG; Park I; Kim Y; Lee HS; Lee W; Yoon S; Lee JL
    Clin Genitourin Cancer; 2024 Apr; 22(2):413-419. PubMed ID: 38228412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
    Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
    Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
    Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
    Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas.
    Zhou Y; Cui Y; Zhang D; Tong A
    J Clin Endocrinol Metab; 2023 Feb; 108(3):755-766. PubMed ID: 36383456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
    Baudin E; Goichot B; Berruti A; Hadoux J; Moalla S; Laboureau S; Nölting S; de la Fouchardière C; Kienitz T; Deutschbein T; Zovato S; Amar L; Haissaguerre M; Timmers H; Niccoli P; Faggiano A; Angokai M; Lamartina L; Luca F; Cosentini D; Hahner S; Beuschlein F; Attard M; Texier M; Fassnacht M; ;
    Lancet; 2024 Mar; 403(10431):1061-1070. PubMed ID: 38402886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
    Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
    Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
    Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
    Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
    Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
    Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies in Pheochromocytoma and Paraganglioma.
    Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
    J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
    Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
    J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic pheochromocytomas and paragangliomas: where are we?
    Prinzi N; Corti F; Torchio M; Niger M; Antista M; Pagani F; Beninato T; Pulice I; Rossi RE; Coppa J; Cascella T; Giacomelli L; Di Bartolomeo M; Milione M; de Braud F; Pusceddu S
    Tumori; 2022 Dec; 108(6):526-540. PubMed ID: 35593402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.
    Hadoux J; Terroir M; Leboulleux S; Deschamps F; Al Ghuzlan A; Hescot S; Tselikas L; Borget I; Caramella C; Déandréis D; Goere D; De Baere T; Schlumberger M; Baudin E
    Horm Cancer; 2017 Dec; 8(5-6):330-337. PubMed ID: 28748315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapies for pheochromocytoma and paraganglioma.
    Jimenez C; Fazeli S; Román-Gonzalez A
    Endocr Relat Cancer; 2020 Jul; 27(7):R239-R254. PubMed ID: 32369773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
    Jasim S; Suman VJ; Jimenez C; Harris P; Sideras K; Burton JK; Worden FP; Auchus RJ; Bible KC
    Endocrine; 2017 Aug; 57(2):220-225. PubMed ID: 28685225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
    Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
    JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.